Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.

Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same period in 2010.  Increased operating expenses for the fourth quarter of 2011 and for the full calendar year compared to the same periods in 2010 are primarily due to increased research and development expenses associated with our Phase 2b PEARL-SC clinical study in patients with Systemic Lupus Erythematosus, or lupus, and our VISTA-16 clinical study in patients with Acute Coronary Syndrome, or ACS.

Anthera ended the fourth quarter of 2011 with approximately $67.4 million in cash and cash equivalents and short-term investments.  This is compared to $93.3 million in cash and cash equivalents and short-term investments for the third quarter ended September 30, 2011.

In conjunction with the release of the fourth quarter 2011 financial report, Anthera will host a conference call at 1 p.m. Eastern Time today, February 21, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 47038854. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854.  The audio replay will be available until February 28, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • In December 2011, the VISTA-16 Data Safety Monitoring Board (
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
    (Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
    (Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
    Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
    ... , REDWOOD CITY, Calif., ... its relationship and the signing of its second agreement this ... drug manufacturer. The new agreement covers three undisclosed pharmaceutical ... January 7. , Under the new agreement, Teva will use ...
    ... Md., Dec. 1 Micromet, Inc. (Nasdaq: MITI ), ... of cancer, inflammation and autoimmune diseases today announced that Bayer ... collaboration and license agreement entered into on January 12, 2009 ... solid tumors. , Under the terms of the agreement, Bayer ...
    Cached Medicine Technology:Codexis Expands Collaboration with Teva 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 2Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 3Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet 4
    (Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
    (Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
    (Date:7/11/2014)... (PRWEB) July 11, 2014 The ... Supplements, Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, ... - Global Trends & Forecasts to 2019 ” ... an analysis and forecasting of the market value ... identifies the driving and restraining factors for the ...
    (Date:7/11/2014)... to a new market research report “Internet of Things ... Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building Automation, Consumer, ... - Global Trends & Forecasts to 2014 - 2020”, ... $1029.5 Billion in 2013, and is expected to reach ... 4.08% from 2014 to 2020. , Browse more ...
    (Date:7/11/2014)... (PRWEB) July 11, 2014 Biostimulants are ... growth in turf and ornamentals. These also help turf ... improve length of roots. Turf, ornamentals, and flowers appear ... Therefore, this usage has increased from the last few ... turf and ornamentals is Europe, with around 40% share ...
    Breaking Medicine News(10 mins):Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
    ... of blood tests over skin tests for detecting people ... effective, reliable and therefore holds promise in detecting latent ... dormant TB infection never actually get a full blown ... cases and offer treatment, which would take the pursuit ...
    ... a breach of trust if the court orders to release a ... and a patient.// The hospital said that it would do everything ... had an abortion at 32 weeks' pregnancy. She plans to take ... Appeal ordered that the woman's files be released to the Medical ...
    ... more number of bus drivers and conductors in India are ... of the bus conductor Ravindra Kamble (34). //Statistics show that ... year have been tested positive for HIV. The BEST’s HIV ... the previous year. ,He took the initiative for ...
    ... stem cell products through an IV line, in the years ... heart muscle in patients who have experienced heart attack for ... distinct advantage of the procedure is that intravenous infusion of ... a healthy donor can reverse heart tissue damage, elimininating the ...
    ... about increased risk of birth defects associated with letrozole, ... commonly given for infertility treatment has been settled//. A ... birth defects associated with letrozole is very similar to ... for infertility for more than 40 years that is ...
    ... that are associated with the menopause and dry eye is ... that the symptom is associated with the menopause or peri-menopause. ... risk of infection or visual impairment. ,The survey, sponsored ... percent of menopausal and peri-menopausal women reported that they experience ...
    Cached Medicine News:Health News:Bad Publicity for the Hospital With Respect To Dwarfism Abortion Case 2Health News:Stem Cell Therapy Regenerates Heart Muscle In Heart Attack Patients 2Health News:Dry Eye Is A Symptom Of Menopause 2
    The BioPro Basal Thumb joint is manufactured from Cobalt Chrome and is used to replace the Trapeziometacarpal joint....
    ... Fusion Screw is a headless ... of variable thread pitch and ... holding power. The Acutrak Fusion ... of the IP and DIP ...
    The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
    A flexible intramedullary-stemmed, one-piece implant developed as an adjunct to resection arthroplasty to help restore function to hands disabled by rheumatoid, degenerative or post-traumatic arthrit...
    Medicine Products: